Fédérico Perche

Dr. Fédérico Perche

Centre de Biophysique Moléculaire, Orléans, Centre-Val de Loire, France
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
LZLin Zhu
Lin Zhu
TWTao Wang
Tao Wang
FPFédérico Perche
Fédérico Perche
ATAnton Taigind
Anton Taigind
VTVladimir P. Torchilin
Vladimir P. Torchilin
Significance: The clinical outcomes of anticancer drugs are compromised by their poor physicochemical properties, low tumor targeting, insufficient bioavailability, and side effects. Matrix metalloproteinase 2 (MMP2) has been found overexpressed in most cancers and responsible for tumor cell proliferation and metastasis. In this study, a self-assembling MMP2-sensitive paclitaxel-containing micellar nanopreparation was developed. Several major drug delivery strategies, including self-assembly, PEGylation, the enhanced permeability and retention effect, stimulus sensitivity, a cell-penetrating moiety, and the concept of prodrug, were used in a collaborative fashion to design this nanoparticle. The nanopreparation showed superior tumor targeting, cell internalization, and antitumor efficacy over its nonsensitive counterpart, free paclitaxel and conventional micelles. This uniquely engineered nanoparticle has potential for effective intracellular delivery of drug into cancer cells.

19 February 2014 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
FPFédérico Perche
Fédérico Perche
SBS. Biswas
S. Biswas
TWT. Wang
T. Wang
LZLin Zhu
Lin Zhu
VTVladimir P. Torchilin
Vladimir P. Torchilin

1 August 2011 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
FPFédérico Perche
Fédérico Perche
TBThierry Benvegnu
Thierry Benvegnu
MBMathieu Berchel
Mathieu Berchel
LLLoic Lebegue
Loic Lebegue
CPChantal Pichon
Chantal Pichon
PMPatrick Midoux
Patrick Midoux


7 March 2013 in Journal of Drug Delivery
Verified
Journal Article
Open access
PDF file
FPFédérico Perche
Fédérico Perche
VTVladimir P. Torchilin
Vladimir P. Torchilin
Liposomes are delivery systems that have been used to formulate a vast variety of therapeutic and imaging agents for the past several decades. They have significant advantages over their free forms in terms of pharmacokinetics, sensitivity for cancer diagnosis and therapeutic efficacy. The multifactorial nature of cancer and the complex physiology of the tumor microenvironment require the development of multifunctional nanocarriers. Multifunctional liposomal nanocarriers should combine long blood circulation to improve pharmacokinetics of the loaded agent and selective distribution to the tumor lesion relative to healthy tissues, remote-controlled or tumor stimuli-sensitive extravasation from blood at the tumor’s vicinity, internalization motifs to move from tumor bounds and/or tumor intercellular space to the cytoplasm of cancer cells for effective tumor cell killing. This review will focus on current strategies used for cancer detection and therapy using liposomes with special attention to combination therapies.

27 October 2012 in Cancer Biology & Therapy
Verified
Journal Article
Closed access
FPFédérico Perche
Fédérico Perche
VTVladimir P. Torchilin
Vladimir P. Torchilin
To determine whether the spheroid culture can be used to evaluate drug efficacy, we have evaluated the toxicity of free or carrier-associated doxorubicin as a single drug or in combination with other antineoplastic agents using the spheroid cultures of drug-resistant cancer cells. Paclitaxel, cisplatin, dexamethasone, mitoxantrone, sclareol or methotrexate were used in combination with doxorubicin. The effect of the treatment protocols on free, micellar and liposomal doxorubicin accumulation in spheroids and on resulting toxicity was evaluated by fluorescence and lactate dehydrogenase release, respectively. Enhanced doxorubicin accumulation and toxicity were observed after spheroid pretreatment with mitoxantrone or paclitaxel. Effects of the drug combination with doxorubicin were sequence dependent, use of doxorubicin as the first drug being the least inducer of toxicity. Finally, spheroids were recognized by a cancer cell-specific antibody. Our results suggest the usefulness of spheroids to evaluate chemotherapy combinations.